These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3204877)

  • 1. [Competitive decrease of rifampicin absorption by a dominant absorption of p-aminosalicylic acid under the simultaneous administration of both drugs].
    Nakagawa H
    Kekkaku; 1988 Oct; 63(10):629-43. PubMed ID: 3204877
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of rectal absorption of rifampicin by sodium para-aminosalicylate dihydrate in human subjects].
    Suzuki R; Nakajima Y; Yagi N; Kenmotsu H; Sekikawa H; Miyazaki S; Mino K; Ohwada S; Kishi F; Hayashi N
    Yakugaku Zasshi; 1994 Nov; 114(11):894-900. PubMed ID: 7853151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic drug monitoring of antituberculosis drugs].
    Goromaru T
    Nihon Rinsho; 1990 Feb; 48 Suppl():1226-8. PubMed ID: 2355527
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
    Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
    Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short course chemotherapy in tuberculous meningitis: a pilot trial.
    Sunakorn P; Pongparit S; Wongrung S
    J Med Assoc Thai; 1980 Jun; 63(6):340-5. PubMed ID: 7410983
    [No Abstract]   [Full Text] [Related]  

  • 7. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
    Panchagnula R; Bansal T; Varma MV; Kaul CL
    Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
    Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
    J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic combinations of p-aminosalicylic acid.
    Wesozowski M
    Pharm Acta Helv; 1977; 52(10):239-46. PubMed ID: 347456
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rifampin in the treatment of children with newly detected intrathoracic tuberculosis].
    Gvasaliia T
    Probl Tuberk; 1984 Apr; (4):46-50. PubMed ID: 6610872
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective inhibition of vitamin B 12 absorption by para-aminosalicylic acid.
    Toskes PP; Deren JJ
    Gastroenterology; 1972 Jun; 62(6):1232-7. PubMed ID: 5050320
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experimental study on rifamicin pharmacodynamics].
    Curci G; Ninni A; Di Mezza F
    Arch Tisiol Mal Appar Respir; 1968 Apr; 23(4):293-314. PubMed ID: 5307453
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic interactions between the tuberculostatics rifampicin, para-aminosalicylic acid and isoniazid.
    Boman G; Borgå O; Hanngren A; Malmborg AS; Sjöqvist F
    Acta Pharmacol Toxicol (Copenh); 1970; 28(1):15. PubMed ID: 5314403
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral mesalamine formulation to be marketed.
    Clin Pharm; 1993 Aug; 12(8):555. PubMed ID: 8222518
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proceedings: Rifampicin adverse effects in intermittent therapy].
    Herrmann H; Eule H; Lau W; Kuhnert R; Fanter D; Kahlau U; Schönert E; Werner E
    Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):146-58. PubMed ID: 4491712
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction of some antitubercular drugs with caraway: implications in the enhancement of drug bioavailability.
    Sachin BS; Monica P; Sharma SC; Satti NK; Tikoo MK; Tikoo AK; Suri KA; Gupta BD; Johri RK
    Hum Exp Toxicol; 2009 Apr; 28(4):175-84. PubMed ID: 19734267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.